All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
Intellia propels into 2024 with CRISPR pipeline updates
Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.
Innate Pharma forges ahead with lacutamab trial post-FDA investigation
The FDA removes a partial clinical hold for Innate’s lacutamab trials following an investigation of a patient’s death.
BMS bags advanced melanoma win for Opdualag in the UK
The MHRA gave Bristol Myers Squibb’s Opdualag marketing authorisation for advanced melanoma as part of Project Orbis.
ARTBIO divulges plans for proprietary isotope manufacturing technology
ARTBIO is developing a proprietary radiotherapy manufacturing technology to overcome distribution and supply chain challenges.
Difficult biotech investment ecosystem forces focus on value
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
FDA revamps EUA guidance for Covid-19 monoclonal antibodies
The FDA released an updated guidance for developing Covid-19 monoclonal antibody treatments for EUAs as variants evolve.
Kronos Bio swivels focus towards multiple myeloma after AML failure
Kronos Bio is prioritising its multiple myeloma therapy after reviewing negative Phase Ib AML data for lanraplenib.
Pharma readies for climate disasters amidst supply chain concerns
Experts discussed the potential impacts of climate change on the pharma supply chain and how companies can prepare for them.
Ironwood seals the deal on VectivBio merger
Ironwood Pharmaceuticals completed an acquisition of the gastrointestinal disease company VectivBio.
Pliant Therapeutics recruits patients for bexotegrast trial amidst lPF race
Pliant Therapeutics doubles down on enrolment for a Phase IIb IPF trial as other industry players also investigate new IPF therapies.